Projects and Grants per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Post Doctoral Fellow, University Of Virginia
1981
Post Doctoral Fellow, Louisiana State University School of Medicine
1979
Residency, Louisiana State University School of Medicine
1977
Residency, Indiana University
1974
Doctor of Medicine, Tufts University
1972
Bachelor of Arts, Cornell University
1969
Fingerprint
Dive into the research topics where Richard Greenberg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration from the last 5 years on country level. Dive into details by clicking on the dots.
-
A Phase 2B, Non-Randomized, Controlled, Open-Label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvated RSVPREF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 y
Greenberg, R. (PI)
11/13/25 → 11/13/27
Project: Research project
-
FORWARD FMGX-CS-302: An Interventional Phase 3, Open-Label, Two-Cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients with Invasive Mold Infections Caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucora
Greenberg, R. (PI) & Simmons, C. (CoI)
Basilea Pharmaceutica International Ltd Allschwil
10/14/25 → 10/14/27
Project: Research project
-
A Single-arm, Open-label, Prospective, Observational Study to Assess the Safety of Sulbactam-Durlobactam, Including the Risk of Hypersensitivity Reactions (Including Anaphylaxis) in Participants With Acinetobacter baumannii-calcoaceticus Complex Infection
Greenberg, R. (PI)
9/24/25 → 9/24/27
Project: Research project
-
Candida 301: An Interventional Efficacy and Safety Phase 3 Double-Blind 2-Arm Study to Investigate IV Followed by Oral Fosmanogepix Compared with IV Caspofungin Followed by Oral Fluconazole in Adult Participants with Candidemia and/or Invasive Candidiasis
Greenberg, R. (PI)
Basilea Pharmaceutica International Ltd Allschwil
12/10/24 → 12/9/26
Project: Research project
-
A Phase 2b, Randomized, Controlled, Open-label Study to Evaluate the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults (#50 years of age) When Administered to Lung and Renal Transplant Recipients Comparing 1 Versus 2 Doses an
Greenberg, R. (PI)
10/31/23 → 10/31/26
Project: Research project
-
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
Greenberg, R. N., Schmidt, D., Reichhardt, D., Roesch, S., Vidojkovic, S., Maclennan, J., Chen, L. M., Gruenert, R., Kreusel, C., Weidenthaler, H., Meyer, T. P. H. & Chaplin, P. J., 2024, In: Human Vaccines and Immunotherapeutics. 20, 1, 2384189.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021
the CoVPN 3006 Study Team, Nov 1 2023, In: Open Forum Infectious Diseases. 10, 11, ofad511.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study
Thompson, G. R., Garcia-Diaz, J., Miceli, M. H., Nguyen, M. H., Ostrosky-Zeichner, L., Young, J. A. H., Fisher, C. E., Clark, N. M., Greenberg, R. N., Spec, A., Kovanda, L., Croos-Dabrera, R. & Kontoyiannis, D. P., Feb 2022, In: Mycoses. 65, 2, p. 186-198 13 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Erratum: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis (Journal of Hepatology (2019) 70(5) (930–940), (S0168827819300297), (10.1016/j.jhep.2018.12.038))
Gwag, T., Meng, Z., Sui, Y., Helsley, R. N., Park, S. H., Wang, S., Greenberg, R. N. & Zhou, C., Apr 2021, In: Journal of Hepatology. 74, 4, p. 1003-1004 2 p.Research output: Contribution to journal › Comment/debate
-
A Paradigm Shift Has Begun: Diarrheal Disease Takes a New Form
Ribes, J. A., Arora, V. & Greenberg, R. N., Oct 15 2019, In: Clinical Infectious Diseases. 69, 9, p. 1553-1554 2 p.Research output: Contribution to journal › Comment/debate